Antibiotic resistance in Neisseria gonorrhoeae is diminishing available treatment options for gonorrhea: Some possible remedies

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 4, 2006, Pages 619-628

  Tapsall, John ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Antibiotics; Antimicrobial resistance; Ceftriaxone; Disease control; Fluoroquinolones; Gonorrhea; Neisseria gonorrhoeae; Syndromic treatment

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZITHROMYCIN; BACTERIAL VACCINE; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFIXIME; CEFPODOXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; ERTAPENEM; GENTAMICIN; KANAMYCIN; MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SPECTINOMYCIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; DIAGNOSTIC PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; GONORRHEA; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION CONTROL; MULTIDRUG RESISTANCE; NEISSERIA GONORRHOEAE; NEWBORN OPHTHALMIA; PACIFIC ISLANDS; PELVIC INFLAMMATORY DISEASE; PENICILLIN RESISTANCE; PREVALENCE; PUBLIC HEALTH; REVIEW; SEXUALLY TRANSMITTED DISEASE; VACCINATION;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GONORRHEA; HUMANS; NEISSERIA GONORRHOEAE;

EID: 33749512799     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.4.619     Document Type: Review

References (43)

1. Gerbase AC, Rowley JT, Heymann DH, Berkley SF, Piot P. Global prevalence and incidence estimates of selected curable STDs. Sex. Transm, Infect. 74(Suppl. 1), S12-S16 (1998).
2. Low N, Daker-White G, Barlow D, Pozniak AL. Gonorrhoea in inner London: results of a cross-sectional study. Br. Med. J. 314, 1719-1723 (1997).
3. Roy K, Wang SA, Meltzer MI. Optimizing treatment of antimicrobial resistant Neisseria gonorrhoeae. Emerg. Infect. Dis. 11, 1265-1273 (2005).
4. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV nfection. Sex. Transm. Infect. 75, 3-17 (1999).
5. Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect. Sex. Reprod. Health 36, 11-19 (2004).
6. Ebrahim SH, McKenna MT, Marks JS. Sexual behaviour: related adverse health burden in the United States. Sex. Transm. Infect. 81, 38-40 (2005).
7. Brunham RC, Plummer FA. A general model of sexually transmitted disease epidemiology and its implications for control. Med. Clin. North Am. 74, 1339-1362 (1990).
8. Anderson RM, May RM. Social heterogeneity in sexually transmitted diseases. In: Infectious Diseases of Humans. Dynamics and Control. Anderson RM, May RM (Eds), Oxford University Press, Oxford, UK, 228-242 (1992).
9. Kihlstrom E, Danielsson D. Advances in biology, management and prevention of infections caused by Chlamydia trachomatis and Neisseria gonorrhoeae. Curr. Opin. Infect. Dis. 7, 25-33 (1994).
10. Haizlip J, Isbey SF, Hamilton HA et al. Time required for elimination of Neisseria gonorrhoeae from the drogenital tract of men with symptomatic urethritis: comparison of oral and intramuscular single-dose therapy. Sex. Transm. Infect. 22, 145-148 (1995).
11. Ropp PA, Hu M, Olesky M, Nicholas RA. Mutations in ponA, the gene encoding penicillin-binding protein 1, and a novel locus, penC, are required for high-level chromosomally mediated penicillin resistance in Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 46, 769-777 (2002).
12. WHO Western Pacific Region Gonococcal Antimicrobial Surveillance Programme. Surveillance of antibiotic susceptibility of Neisseria gonorhoeae in the WHO Western Pacific Region 1992-1994. Genitourin. Med. 73, 355-361 (1997).
13. The WHO Western Pacific Gonococcal Antimicrobial Surveillance Programme. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific Region, 2004. Comm. Dis. Intell 30, 129-132 (2006).
14. Ray K, Bala M, Kumari S et al. Antimicrobial resistance of Neisseria gonorrhoeae in selected World Health Organization Southeast Asian Region countries: an overview. Sex. Tansm. Dis. 32, 178-184 (2005)
15. Iverson CJ, Wang SA, Lee MV et al. Fluoroquinolone resistance among Neisseria gonorrhoeae isolates in Hawaii, 1990-2000: role of foreign importation and increasing endemic spread. Sex. Transm. Dis. 31, 702-708 (2004).
16. Tapsall JW, Shultz TR, Phillips EA. Characteristics of Neisseria gonorrhoeae isolated in Australia showing decreased sensitivity to quinolone antibiotics. Pathology 24, 27-31 (1992).
17. Tapsall JW, Phillips EA, Shultz TR, Thacker C. Quinolone resistant Neisseria gonorrhoeae isolated in Sydney, Australia 1991-1995. Sex. Transm. Dis. 23, 425-428 (1996).
18. Tapsall JW, Limnios EA, Shultz TR. Continuing evolution of the pattern of quinolone resistance in Neisseria gonorrhoeae isolated in Sydney, Australia. Sex. Transm. Dis. 25, 415-417 (1998).
19. Dan M. The use of fluoroquinolones in gonorrhoea: the increasing problem of resistance. Expert Opin. Pharmacother. 5, 829-854 (2004).
20. Berglund T, Unemo M, Olcen P, Giesecke J, Fredlund H. One year of Neisseria gonorrhoeae isolates in Sweden: the prevalence study of antibiotic susceptibility shows relation to the geographic area of exposure. Int. J. STD AIDS 13(2), 109-114 (2002).
21. Martin IMC, Hoffman S, Ison CA on behalf of the European Surveillance of Sexually Transmitted Infections (ESSTI) network. European surveillance of sexually transmitted infections (ESSTI): the first combined antimicrobial susceptibility data for Neisseria gonorrhoeae in Western Europe. J. Antimicrob. Chemother. 8, 587-593 (2006).
22. Herida M, Desenclous JC, Martin IM, Goulet V, Laurent E, Sednaoui P. Increase of Neisseria gonorrhoeae ciprofloxacin resistance in France in 2001-2003. Sex. Transm. Dis. 33(1), 6-7 (2006).
23. Trees DL, Sandul AL, Neal SW, Higa H, Knapp JS. Molecular epidemiology of Neisseria gonorrhocae exhibiting decreased susceptibility and resistance in Hawaii, 1991-1999. Sex. Transm. Dis. 28, 309-314 (2001).
24. Galarza P. Pagano I, Oviedo C et al. Molecular epidemiology of ciprofloxacin resistant Neisseria gonorrhoeae strains isolated in Argentina. Proceedings of the 16th Biennial Meeting of the International Society for Sexually Transmitted Diseases Research. Amsterdam, The Netherlands, WP-003 (2005).
25. Yagupsky P, Schahar A, Peled N et al. Increasing incidence of gonorrhoea in Israel associated with countryside dissemination of a ciprofloxacin-resistant strain. Eur. J. Clin. Microbiol. Infect. Dis. 21, 368-372 (2002).
26. Moodley P, Zimba T, Appalata T, Sturm AW. Increase in prevalence of ciprofloxacin resistant N. gonorrhoeae in Kwazulu-Natal. Proceedings of the 16th Biennial Meeting of the International Society for Sexually Transmitted Diseases Research. Amsterdam, The Netherlands, WP-018 (2005).
27. Lewis DA, Prentice E, Smith AM, Hijazi L, Tsaagane L. Characterization of ciprofloxacin-resistant gonococci isolated in Gautang province. Proceedings of the 16th Biennial Meeting of the International Society for Sexually Transmitted Diseases Research. Amsterdam, the Netherlands, WO-019 (2005).
28. Shultz TR, Tapsall JW. White PA. Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC. Antimicrob. Agents Chemother 45, 734-738 (2001).
29. Muratani T, Akasaka S, Kobayashi T et al. Outbreak of cefozopran (penicillin, oral cephems, and aztreonam)-resistant Neisseria gonorrhoeae in Japan. Antimicrob. Agents Chemother. 45, 3603-3606 (2001).
30. Ameyama S, Onodera S, Takattata M et al. Mosaic-like structure of penicillin-binding protein 2 gene (penA) in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime. Antimicrob. Agents Chemother. 46, 3744-3749 (2002).
31. Boslego JW, Tramont EC, Takafuji ET et al. Effect of spectinomycin use on the prevalence of spectinomycin-resistant and of penicillinase-producing Neisseria gonorrhoeae. N. Engl. J. Med. 317, 272-278 (1987).
32. Sutrisna A, Soebjakto O, Wignall FS et al. Increasing resistance to ciprofloxacin and other antibiotics in Neisseria gonorrhoeae from East Java and Papua, Indonesia in 2004 - implications for treatment. Int. J. STD AIDS. (2006) (In press).
33. Ieven M, van Looveren M, Sudigoadi S et al. Antimicrobial susceptibilities of Neisseria gonorrhoeae strains isolated in Java, Indonesia. Sex. Transm. Dis. 30, 25-29 (2003).
34. Daly CC, Hoffman I, Hobbs M et al. Development of an antimicrobial susceptibility surveillance system for Neisseria gonorrhoeae in Malawi: comparison of methods. J. Clin. Microbiol. 35, 2985-2988 (1997).
35. Lkhamsuren E, Shultz TR, Limnios EA, Tapsall JW. The antibiotic susceptibility of Neisseria gonorrhoeae isolated in Ulaanbaatar, Mongolia. Sex. Transm. Infect. 77, 218-219 (2001).
36. Handsfield HH, Dalu ZA, Martin DH et al. Multicenter trial of single-dose azithromycin vs ceftriaxone in the treatment of uncomplicated gonorrhea. Sex. Transm. Dis. 21, 107-111 (1994).
37. Livermore DM, Alexander S, Marsden B et al. Activity of ertapenem against Neisseria gonorrhoeae. J. Antimicrob. Chemother. 54(1), 280-281 (2004).
38. Simonsen GS, Tapsall JW, Allegranzi B, Talbot EA, Lazzari S. The ARCS approach - a public health tool for antimicrobial resistance containment and surveillance. Bull. World Health Organ. 82, 928-934 (2004).
39. Livermore DM. Minimising antibiotic resistance. Lancet Infect. Dis. 5, 450-459 (2005).
40. Tapsall JW. What management for gonorrhoea in the post quinolone era? Sex. Transm. Dis. 33(1), 8-10 (2006).
41. Turnidge J, McCarthy LR, Master RN, Kepner DE. Low levels of fluoroquinolone resistance in Escherichia coli. A five-year trend in Australia through use of TSN database Australia. Commun. Dis. Intell. 27(Suppl.), S89-S91 (2003).
42. Unicomb L, Ferguson J, Riley TV, Collignon P. Fluoroquinolone resistance in Campylobacter absent from isolates, Australia. Emerg. Infect. Dis. 9(11), 1482-1483 (2003).
43. Bauer HM, Mark KE, Samuel M et al. Prevalence of and associated risk factors for fluoroquinolone-resistant Neisseria gonorrhoeae in California, 2000-2003. Clin. Infect. Dis. 41, 795-803 (2005).